Differences in clinical outcomes between men and women, including mortality rates and complications, have been reported in cardiovascular (CV) disease for many years. Although progress has been made in reducing both the morbidity and the mortality of heart disease in both men and women since 1980, the decrease in observed events has been less in women. 1 Whether this is related to underlying biologic differences or disparities in care as a result of inadequate treatment is still unclear. Furthermore, the fact that these differences in outcomes remain in an era of overall declining mortality from CV disease, as well as improved treatment of risk factors and increased recognition of CV disease among women, further supports the existence of sex-specific differences.
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In a previous issue of Angiology, Gijsberts et al sought to answer this very question. Their findings are interesting and merit further discussion. 2 Of the 1763 participants (only 480 of whom were women) in the Utrecht Coronary Biobank (UCORBIO) cohort of a Dutch population undergoing coronary angiography, the overall incidence of major adverse cardiac events (MACE) over a mean 2.1-year follow-up was nearly identical among men and women (20.7% vs 21.3%, P ¼ .744). 2 What the investigators also found, however, is that both women who underwent angiography for myocardial infarction (MI) and women who had multivessel disease had a higher hazard ratio for MACE as compared with men (1.66 and 1.41, respectively). This finding is not at all surprising, given the recent evolving knowledge on the pathophysiology of both heart failure and coronary artery disease (CAD) in women.
Women and Heart Failure With Preserved Ejection Fraction
Women with acute decompensated heart failure tend to have heart failure with preserved ejection fraction (HFpEF) almost twice as often as men, and those with impaired left ventricle (LV) systolic function tend to present with a higher left ventricular ejection fraction than men. 3 The sex differences in heart failure mechanisms have been described in a variety of settings, including pressure overload from hypertension 4 and aortic stenosis 5 as well as CAD. 6 In the Framingham study, women had increased LV wall thickness without dilation in response to hypertension whereas in men, there was chamber dilation without significant changes in wall thickness. Masoudi et al demonstrated that among patients with prior MI, women were more likely to have preserved LV systolic function, which raises the possibility of sex differences in ventricular remodeling post-MI. 6 The women in the UCORBIO cohort were older and had more hypertension as compared with the men. Importantly, the levels of brain natriuretic peptide and diuretic use were higher among the women, thus suggesting a higher prevalence of heart failure, despite similarities in infarct size. 2 Therefore, the observed increased mortality in women following angiography for MI may be explained by heart failure. The prognosis of patients with HFpEF, although less ominous than that for patients with systolic heart failure, does exceed that for agematched control patients. 7 Early studies of medical therapy for heart failure demonstrated both improved symptoms and survival; however, only about 20% of those enrolled were women, and these studies routinely excluded the elderly patients and those with preserved systolic function. 8 Later studies enrolling patients with HFpEF have not demonstrated the same promising results as those with systolic heart failure, thus suggesting that the pathophysiology is different. As a result, there are no approved therapies to date for reducing mortality or hospitalizations in HFpEF. 9 An important consideration in developing therapeutic targets will not only be to understand the underlying biologic mechanisms resulting in HFpEF but also the recognition that women and men respond differently to drug therapies. For example, aspirin reduces the risk of MI in men by 32% but has no effect on ischemic stroke whereas in one large study of women, aspirin had no effect on MI but reduced the risk of stroke by 24%, thus underscoring that there are sex-specific responses to medications. 10 
Women and Multivessel CAD
The finding that women with multivessel disease had a worse outcome than men also suggests that the pathophysiology of CAD may be a different process in women. Coronary microvascular dysfunction in the absence of obstructive CAD and myocardial disease disproportionately affects women and this can result in myocardial ischemia. 11 In addition, in these women, cholesterol plaque can ultimately accumulate in coronary arteries and result in major blockages, despite an initial diagnosis of ''clear'' coronary arteries and the erroneousassociated prediction for low risk of future coronary events. 11 In the National Heart, Lung and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study, women with microvascular disease as assessed by coronary flow reserve had an increased risk of major adverse cardiac events. 12 Therefore, the worse outcomes in women in the present study with multivessel disease may represent a group with more extensive microvascular disease. To date, there are no specific guideline-directed therapies for patients with microvascular angina, which represents an opportunity for future drug development.
Inflammation and CV Risk
Inflammation represents a major postulated mechanism for many disease states, and a mechanistic role in single or multivessel CAD in women is no exception. Specific factors thought to be causative for low-grade inflammation, and increased autoimmune disease include acylation stimulating protein, asymmetric dimethylarginine, creatinine, lipoprotein(a) [Lp(a)], platelet-activating factor acetylhydrolase, and thyroid-stimulating hormone. 13 Possible biomarkers for increased CAD risk in women include high-sensitivity Creactive protein (hsCRP), interleukin 6 (IL-6), and Lp(a) as assessed by Spoletini et al in postmenopausal women, although this observed association does not establish a definite link of the biomarkers and CAD, necessitating further study and confirmation. 14 However, to add to the confusion, studies of any inflammatory effect of estrogen have been reported to show that estrogen in physiological levels, pregnancy levels, and with hormone replacement therapy (HRT), all inhibit secretion of proinflammatory cytokines, stimulate synthesis and secretion of anti-inflammatory cytokines, and also decrease cell responses to lipopolysaccharide-induced inflammation. 15 With such an observation, other considerations such as an increased responsiveness to inflammation-inducing factors or increased levels of these factors in certain situations in women are appropriate. An example is metabolically benign obesity as noted in 1889 postmenopausal women from the nested case-control stroke study of the Women's Health Initiative Observational Study, where Wildman et al found that overweight/obese women with 2 metabolic syndrome (MetS) components or diabetes mellitus (DM) had the highest odds ratio (OR) for 3 inflammatory markers in the top quartile (OR 4.2; 95% confidence interval: 2.9-5.9). 16 
Biomarkers of Inflammation and CV Risk
In a review of various inflammatory markers (additional markers not already mentioned include metallic metalloproteinase-9, monocyte chemotactic protein 1, lipoprotein-associated phospholipase A2, and tumor/tissue necrosis factor a) and their occurrence with coronary artery calcification (CAC), Hamirani et al found a weak association with CAC, mainly in women and by univariate analysis, the association of which was lost after obesity and body mass index corrections. 17 Nevertheless, such an observation is consistent with the association of increased inflammation with CAD in women. It was stated by Krintus et al that the complex multifactorial etiology of CAD goes beyond inflammatory risk factors to include such factors as electrocardiogram results, lipid profile, renal function, imaging, and clinical parameters. 18 Observations contributing further to the importance of inflammation in women involve inflammatory bowel disease which, in a review by Singh et al, was shown to have a modest association with increased CV morbidity risk from stroke and CAD, especially in women. 19 Beyond inflammatory markers, many other considerations are essential to assess CAD risk due to its complex etiology involving multiple factors which include electrocardiography, imaging, clinical presentation, and multiple laboratory studies including values such as blood lipids, indicators of kidney pathology, LV functional status, and troponins as indicative of cardiac necrosis. 18 
Hormone Replacement Therapy and Inflammation
In an assessment of the Women's Health Initiative (WHI) study, Langer et al assessed HRT in selected postmenopausal women without known pre-existing CV disease and studied 304 patients who had developed CAD and 304 controls. 20 These authors found that HRT patients had higher levels of hsCRP, high-density lipoprotein cholesterol, and triglycerides with hsCRP highest in those taking conjugated equine estrogen alone; these patients had decreased levels of tissue plasminogen activator (tPA) antigen and homocysteine. 20 With estrogen plus progestin, patients who had CAD events had higher hsCRP, IL-6, tPA-antigen, total cholesterol, and triglycerides. 20 The bottom line from the study of Langer et al is that there appear to be multiple HRT CV biomarker differences that need further resolution by clinical trials. 20 In another substudy of the WHI, Rossouw et al investigated 359 cases of CAD events versus 820 controls and found that multiple lipid, inflammatory, and thrombotic biomarkers had an association with CAD in postmenopausal women but only low-density lipoprotein cholesterol interacted significantly with HRT to increase the risk for CAD events. 21 Time from menopause is a key factor when considering HRT with the early postmenopausal woman appearing to possibly receive CV benefit from HRT because of the greater endothelial response to estrogen which may decrease any harmful coagulation effect. 22 Method of administration of HRT may also make a difference and in a review, Lakoski and Herrington found that hsCRP levels were elevated in most postmenopausal women taking oral HRT, whereas this elevation was not the case with transdermal estrogen. 23 
Metabolic Syndrome
In patients with abnormal glucose tolerance or DM, there is an increased CV risk, especially involving women. In contrast to the WHI, where DM was not associated with increased CV risk in postmenopausal women taking HRT, Howard et al found that in a study of 423 women with atherosclerosis confirmed by angiograms, there was increased evidence of CAD and worsening of various inflammatory markers in women with DM or abnormal glucose tolerance who received HRT. 24 It was concluded by these authors that female patients with DM should not receive HRT. In a substudy of the WHI, Wildman et al found that in an assessment of 1889 postmenopausal women, obese women with 2 MetS components or with DM had the greatest chance of having 3 increased inflammatory CV risk markers. 16 In the WISE study, Kip et al studied 780 women submitted to coronary angiography because of possible myocardial ischemia. 25 They found that there was a significant relationship between MetS and increased body mass index but only MetS had a significant association with MACE or with risk of death over 3 years. 25 Such results in association with MACE show the powerful predictive value of MetS in women regarding CV risk which is not seen with obesity alone.
Modification of Inflammation to Reduce CV Risk
Favorable modification of inflammatory risk factors is of major interest and Soares and de Sousa reviewed 15 selected articles with women as the protagonist and found that 12 of 15 articles showed decreased inflammatory biomarkers in association with exercise. 26 Inflammatory risk status was the major factor in the Justification for the Use of Statins in Primary prevention: An intervention Trial evaluating Rosuvastatin (JUPITER) trial. The findings in JUPITER centered on patients with hsCRP 2 mg/L and low-density lipoprotein cholesterol <130 mg/ dL with no perceived CV risk indication for a statin; these patients had a higher probability of being female, 27 consistent with a greater association of inflammation with CAD in women. In these JUPITER patients, including women, rosuvastatin use resulted in a significant decrease in the occurrence of major CV events. 28 Inflammation appears to play a major role in singleand multivessel CAD in women.
Conclusion
The differences between women and men regarding CAD are complex. Not only do the clinical presentations vary, but gender differences in risk factors and response to treatment of these risk factors appear to differ between women and men. 29 Undoubtedly, hormones and inflammation play major roles in these differences. In the UCORBIO cohort of patients undergoing coronary angiography, Gijsberts et al found that women who had sustained an MI or who had multivessel CAD had higher hazard ratios than men for MACE, whereas overall MACE was essentially the same for both sexes. 2 Possible explanations for these observations may be associated with the different responses to medication such as less aspirin benefit in women regarding MI, 10 increased inflammation associated with CAD in women, 14 the effects of oral HRT on inflammation, 23 and the increased association of MetS with MACE. 25 Also, the increased role played by coronary microvascular disease in women may be of relevance. 11 A specific explanation of sex differences and the UCORBIO observations is still not forthcoming but part of it most likely lies with the possibilities discussed.
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